Evotec SE (EVT DU) stock market data APIs
€7.4702
-0.07(-0.9%)
as of July 18, 2025
Try our APIs with
free plan!
Evotec SE Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EVT.DU.
Prev. Close
7.4702
Open
7.4007
High
7.472
Low
7.4007
52 wk Range
5.07-10.63
Market Cap
7 158 M
EPS
-0.09
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evotec SE data using free add-ons & libraries
Get Evotec SE Fundamental Data
Evotec SE Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-04-24
- EPS/Forecast: 0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evotec SE News
New
Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes
Sernova (SVA.TO) on Wednesday said it signed a collaborative research agreement with Eledon Pharmace PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Here Is What You Need To Know Before Investing In Evotec SE (EVO)
Evotec SE (NASDAQ:EVO) is among the 13 Best German Stocks to Invest in Now. The company’s shares have gained over 9% in the past month, as of the close of business on July 2, amid positive recent de...
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxal...
Evotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug Discovery
Evotec SE (NASDAQ:EVO) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company said it would participate in the NURTuRE-AKI consortium to investigate acute ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
